388082-77-7 Lapatinib ditosylate AKSci J99158
 
 
Loading Please Wait...
  J99158    
Lapatinib ditosylate
, 98%
 
GW572016

Structure N/A

IDENTITY
CAS Number:388082-77-7
MDL Number:MFCD09264195
MF:C29H26ClFN4O4S.2C7H8O3S
MW:925.46
SPECIFICATIONS & PROPERTIES
Purity:98%
Physical Form:Yellow crystalline powder or solid
Melting Point:240-242°C
Long-Term Storage:Store long-term at -20°C

BIOLOGICAL INFO
Solubility:DMSO: 185mg/mL; H2O: <1mg/mL; EtOH: <1mg/mL
Application(s):Potent EGFR and ErbB2 inhibitor
Form:Ditosylate

REVIEW

 Lapatinib is a 4-anilinoquinazoline kinase inhibitor of the intracellular tyrosine kinase domains of both epidermal growth factor receptor (HER1/EGFR/ERBB1) and human epidermal growth factor receptor type 2 (HER2/ERBB2)with a dissociation half-life of =300 minutes. Lapatinib inhibits ERBB-driven tumor cell growth in vitro and in various animal models. An additive effect was demonstrated in an in vitro study when lapatinib and 5-florouracil (the active metabolite of capecitabine) were used in combination in the 4 tumor cell lines tested. The growth inhibitory effects of lapatinib were evaluated in trastuzumab-conditioned cell lines. Lapatinib retained significant activity against breast cancer cell lines selected for long-term growth in trastuzumab-containing medium in vitro. These in vitro findings suggest non-cross-resistance between these two agents.

REFERENCES
[1]Nelson MH, Dolder CR: Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother. 2006 Feb;40(2):261-9. Epub 2006 Jan 17.
[2] Burris HA 3rd: Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist. 2004;9 Suppl 3:10-5.
[3] 'Burris HA 3rd, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O''Neil B, Marcom PK, Ellis MJ, Overmoyer B, Jones SF, Harris JL, Smith DA, Koch KM, Stead A, Mangum S, Spector NL: Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol. 2005 Aug 10;23(23):5305-13. Epub 2005 Jun 13. '
[4] Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006 Dec 28;355(26):2733-43.

GHS

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501


RELATED PRODUCTS
Q570Lapatinib
A817Lapatinib ditosylate
B402Lapatinib ditosylate monohydrate
W46955-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl)furan-2-carbaldehyde
B644N-[3-Chloro-4-(3-fluorobenzyloxy)phenyl]-6-iodoquinazolin-4-amine
B6463-Chloro-4-(3-fluorobenzyloxy)aniline

Current as of April 22, 2019


Download SDS

CATEGORIES

 APIs and Bioactives > Protein Kinase Inhibitors


PubChem